Company / EPS (Diluted)
Perspective Therapeutics, Inc. EPS (Diluted) History
FY2013-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.08
FY2021
5-year range
-$0.12 / -$0.08
FY2017-FY2021
Trend
+33.3%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2021 after 3 years of decline, reaching $-0.08.
Based on SEC 10-K filings.
-0.08 in FY2021.
Improved from $-0.11 to $-0.08 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, eps (diluted) increased 33.3% year-over-year.
- Peak eps (diluted) was recorded in FY2017.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | -$0.08 | +33.3% |
| FY2020 | -$0.12 | -9.1% |
| FY2019 | -$0.11 | -22.2% |
| FY2018 | -$0.09 | -28.6% |
| FY2017 | -$0.07 | +56.3% |
| FY2016 | -$0.16 | -45.5% |
| FY2015 | -$0.11 | +0.0% |
| FY2014 | -$0.11 | +8.3% |
| FY2013 | -$0.12 | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026